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Abstract
Background: Anemia is common among people living with HIV infection (PLWH) and is associated with adverse
health outcomes. Information on risk factors for anemia incidence in the current antiretroviral therapy (ART) era is
lacking.
Methods: Within a prospective clinical cohort of adult PLWH receiving care at eight sites across the United States
between 1/2010–3/2018, Cox proportional hazards regression analyses were conducted among a) PLWH free of
anemia at baseline and b) PLWH free of severe anemia at baseline to determine associations between time-
updated patient characteristics and development of anemia (hemoglobin < 10 g/dL), or severe anemia (hemoglobin
< 7.5 g/dL). Linear mixed effects models were used to examine relationships between patient characteristics and
hemoglobin levels during follow-up. Hemoglobin levels were ascertained using laboratory data from routine clinical
care. Potential risk factors included: age, sex, race/ethnicity, body mass index, smoking status, hazardous alcohol use,
illicit drug use, hepatitis C virus (HCV) coinfection, estimated glomerular filtration rate (eGFR), CD4 cell count, viral
load, ART use and time in care at CNICS site.
Results: This retrospective cohort study included 15,126 PLWH. During a median follow-up of 6.6 (interquartile
range [IQR] 4.3–7.6) years, 1086 participants developed anemia and 465 participants developed severe anemia.
Factors that were associated with incident anemia included: older age, female sex, black race, HCV coinfection,
lower CD4 cell counts, VL ≥400 copies/ml and lower eGFR.
Conclusion: Because anemia is a treatable condition associated with increased morbidity and mortality among
PLWH, hemoglobin levels should be monitored routinely, especially among PLWH who have one or more risk
factors for anemia.
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Background
Anemia (hemoglobin < 10 g/dL) and severe anemia
(hemoglobin< 7.5 g/dL) [1] are common among people
living with HIV (PLWH) [2], and the prevalence of
anemia increases with HIV disease severity [3, 4]. While
estimates of anemia prevalence vary depending on fac-
tors including age, setting, HIV disease stage, use of anti-
retroviral therapy (ART), sex, and injection drug use
status [2, 3], it is estimated that 18–32% of PLWH with-
out AIDS and 48–85% of PLWH with clinical AIDS have
anemia in the United States, compared to 15–17% of
people living without HIV [3, 5]. Many of the aforemen-
tioned prevalence estimates date from before or early in
the ART era before the current treatment initiation
guidelines and improvements in HIV care [6].
Anemia is thought to be an independent prognostic in-
dicator among PLWH, associated with HIV disease pro-
gression [2, 7]. Furthermore, previous studies have
reported associations between anemia and mortality [4,
8–10], health-related quality-of-life, dementia [11], and
treatment failure [12] among PLWH.
The causes of anemia among PLWH are multifactorial.
Immune dysregulation during HIV infection can in-
crease anemia risk through red blood cell destruction
(hemolysis) or ineffective red blood cell production,
which are influenced by infections of the spleen or circu-
latory system [13]. Blood loss among PLWH is not un-
common and may occur as a result of neoplastic disease
or gastrointestinal lesions accompanying opportunistic
infections. Additional mechanisms for HIV-related
anemia include deficiencies of vitamin B12, folate, or
iron [13].
The goal of this study was to estimate the association
between patient characteristics and (a) risk of anemia,
(b) risk of severe anemia, or (c) a lower hemoglobin level
to identify risk factors for anemia among a large cohort
of PLWH within the US in the modern HIV treatment
era.
Methods
Overview and setting
This study included PLWH in care in the Centers for
AIDS Research (CFAR) Network of Integrated Clinical
Systems (CNICS) cohort during January 1, 2010 to
March 31, 2018. The CNICS cohort has been described
in detail elsewhere [14]. Briefly, CNICS is a dynamic
prospective clinical cohort of more than 32,000 PLWH
≥18 years of age receiving care at eight participating aca-
demic sites across the US. Comprehensive clinical data,
including diagnoses, medications (including ART), la-
boratory test results, demographic information, and his-
torical information, including ART use before
enrollment, are collected through electronic medical re-
cords and other institutional data systems at each site
and harmonized in the CNICS data repository. Medica-
tion data, including ART use, is entered into the elec-
tronic medical records by clinicians or prescription fill/
refill data are uploaded directly from Pharmacy Systems
and verified through medical record review. Patient re-
ported measures and outcomes data (PROs) are col-
lected in the CNICS assessment as part of routine
clinical care appointments [15, 16]. However, sites varied
in their year of PRO initiation, so it is available for the
majority but not all CNICS participants. The CNICS
clinical assessment of PROs includes measures of smok-
ing, alcohol use and illicit drug use. Participants entered
the present study on January 1, 2010 or the earliest date
that they had been enrolled in CNICS for 6 months,
whichever came later (baseline). Additional exclusions
were made for participants without PRO data, or for
those with less than two available hemoglobin lab values
during the study years (Fig. 1). Informed consent was
obtained from all participants to be part of CNICS and
institutional review boards at each site approved CNICS
protocols.
Participant characteristics
Characteristics that were analyzed as potential risk fac-
tors for anemia, severe anemia or a lower hemoglobin
level included the following characteristics analyzed at
baseline: age, sex, race/ethnicity, BMI (closest available
BMI, categorized as < 18.5, 18.5- < 25, 25- < 30, ≥30 kg/
m2), smoking status (never, former, current), hazardous
alcohol use (a score of ≥4 for women or ≥ 5 for men on
the Alcohol Use Disorders Identification Test (AUDIT-
C) scale [17]) illicit drug use (use of cocaine/crack,
methamphetamines/crystal and/or illicit opioids, using
the Alcohol, Smoking and Substance Involvement
Screening Test (ASSIST) [18]). In addition, the following
characteristics were analyzed as potential time-updated
risk factors: hepatitis C virus (HCV) coinfection, kidney
function measured using estimated glomerular filtration
rate (eGFR, categorized as < 30, 30–59, or ≥ 60mL/mi-
nute/1.73 m2), CD4 cell count (categorized as ≥500,
350–499, 200–399, 100–199 or < 100 cells/mm3), detect-
able viral load (VL, ≥400 copies/ml), treatment with
ART and time in care at CNICS site, defined as time
from enrollment in CNICS until the last available
CNICS activity (either last lab date or last visit). In
addition, we adjusted for CNICS site. All covariates were
selected a priori, based on review of the literature and
clinical knowledge.
Outcome ascertainment
Hemoglobin levels, expressed in grams per deciliter (g/
dL), were ascertained using inpatient and outpatient la-
boratory data obtained as part of routine clinical care.
Outcomes included incident anemia (the first hemoglobin
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measure below 10 g/dL), incident severe anemia (the first
hemoglobin measure below 7.5 g/dL), and changes in
hemoglobin level. Additional interest lay in investigating
associations between patient characteristics and chronic
anemia, defined as anemia lasting for at least 6 months,
identified using hemoglobin lab results on two separate
occasions at least 6 months apart which were consistently
in the anemic range without any additional hemoglobin
values above the anemia range during that six-month
period.
Statistical analysis
Two multivariable Cox proportional hazards regression
analyses were conducted. First, among the subset of
PLWH who did not have a history of anemia at baseline,
associations were measured between risk factors and de-
velopment of anemia. Second, among the subset of par-
ticipants who did not have a history of severe anemia at
baseline, associations were measured between risk fac-
tors and development of severe anemia. Participants
were censored at (a) the time they developed anemia
(for the incident anemia analyses) or at the time they de-
veloped severe anemia (for incident severe anemia ana-
lyses), (b) at the time of last activity in CNICS, (c) at the
time of death or (d) at the time of administrative censor-
ing due to end of follow-up per site, whichever came
first. The timescale for the models was time since base-
line. In post hoc analyses, we estimated the risk of
anemia for subgroups identified as having combinations
of high risk characteristics and tested for interaction on
a multiplicative scale.
Linear mixed effects models were used to examine the
associations between patient characteristics and
hemoglobin levels among all PLWH. Mixed-effects
models utilize random intercepts and slopes for time at
the participant level to handle irregular patterns of re-
peated measures over follow-up [19].
Sensitivity analysis
In a sensitivity analysis, we assessed associations between
patient characteristics and chronic anemia (defined as
anemia lasting for at least 6 months) using a Cox pro-
portional hazards regression model among the popula-
tion who were anemia-free at baseline. Because factors
such as severe bleeding, blood donation and blood trans-
fusion could impact hemoglobin levels at a given time
point and are difficult to capture, this sensitivity analysis
allowed us to describe associations among those with
chronic anemia.
All analyses were performed using Stata version 14.2.
Results
There were 15,126 PLWH who were included in these
analyses (Fig. 1). A total of 12,249 (81%) did not have a
history of anemia at baseline, and 14,301 (95%) did not
have a history of severe anemia at baseline. Participants
Fig. 1 Flow chart for inclusion/exclusion criteria
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had a median of 14 hemoglobin values measured during
a median follow-up of 6.6 (interquartile range [IQR]
4.3–7.6) years. Table 1 provides baseline characteristics
for all study participants, as well as characteristics for
the 1086 participants who developed anemia and 465
participants who developed severe anemia during
follow-up. For the overall population, the median age of
study participants was 44 (IQR 35–51) years at baseline,
17% were female, 17% were co-infected with HCV, and
80% were using ART.
The incidence of anemia was 1.95/100 person-years
and the incidence of severe anemia was 0.68/100
person-years. Characteristics associated with incident
anemia included older age, female sex, black race/
Table 1 Baseline demographic and clinical characteristics of PLWH in care at sites across the United States overall and by anemia
statusa
Participant characteristics All participants
(N = 15,126)
Developed anemia
during follow-up
(n = 1086)
Developed severe
anemia during
follow-up (n = 465)
Age (median, IQR) 44 (35–51) 46 (39–53) 46 (39–53)
Female 2620 (17) 303 (28) 156 (34)
Race/ethnicity
White 6712 (44) 411 (38) 148 (32)
Black 5560 (37) 529 (49) 243 (52)
Hispanic 2145 (14) 108 (10) 56 (12)
Other/missing 709 (5) 38 (3) 18 (4)
Years in CNICS at baseline (median, IQR) 1.1 (0.5–6.0) 2.2 (0.5–7.0) 3.0 (0.5–7.7)
Viral load ≥400 copies/ml 3314 (22) 338 (31) 170 (37)
CD4 count (cells/mm3)
< 100 777 (5) 107 (10) 78 (17)
100–199 1236 (8) 99 (9) 64 (14)
200–349 2686 (18) 219 (20) 122 (26)
350–499 3323 (22) 233 (22) 79 (17)
≥ 500 7104 (47) 428 (39) 122 (26)
Hepatitis C virus coinfection 2556 (17) 321 (30) 146 (31)
Kidney function (eGFR)
< 30 164 (1) 25 (2) 23 (5)
30–59 620 (4) 51 (5) 34 (7)
≥ 60 14,342 (95) 1010 (93) 408 (88)
BMI (kg/m2)
< 18.5 352 (2) 24 (2) 20 (4)
18.5 to < 25.0 6494 (43) 472 (44) 207 (44)
25.0 to < 30.0 5199 (34) 339 (31) 128 (28)
≥ 30.0 3081 (21) 251 (23) 110 (24)
ART use 12,070 (80) 821 (76) 351 (75)
MCV (fL) 91 (87–95) 91 (86–96) 90 (85–96)
Smoking status
Never 6211 (41) 408 (38) 188 (41)
Former 3492 (23) 195 (18) 80 (17)
Current 5423 (36) 483 (44) 197 (42)
Hazardous alcohol useb 4239 (28) 244 (22) 110 (24)
Illicit drug usec 2283 (15) 165 (15) 64 (14)
a Baseline was defined as the earliest date during January 1, 2010- March 31, 2018 that a person had 6+ months in CNICS care
b Hazardous alcohol use defined a score of ≥4 for women or ≥ 5 for men on the AUDIT-C scale
c Use of cocaine/crack, methamphetamines/crystal, and/or illicit opioids
Abbreviations: ART antiretroviral therapy, BMI body mass index, eGFR estimated glomerular filtration rate, MCV mean corpuscular volume PLWH people living with HIV
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ethnicity, HCV coinfection, lower CD4 cell count, higher
viral load, and lower eGFR, indicative of poor kidney
function (Table 2). Risk factors associated with severe
anemia were similar to those for anemia with the excep-
tion of older age and black race/ethnicity (Table 2). In
post hoc analyses, we estimated the risk of anemia for
subgroups identified as having combinations of high risk
characteristics, including CD4 < 100, female sex, and co-
infection with HCV. Among women, CD4 < 100 as com-
pared with CD4 ≥ 500 was associated with a HR for
incident anemia of 10.64 (95% CI 8.41, 13.47), while for
men the HR was 4.11 (2.60, 6.52); p-value for low CD4-
sex interaction < 0.001; Supplemental Table 1). Among
those with HCV coinfection, CD4 < 100 was associated
with a HR for incident anemia of 10.20 (95% CI 8.01,
12.98), while for those without HCV coinfection, the HR
was 5.01 (95% CI 3.39, 7.42; p-value for low CD4-
HCVcoinfection interaction =0.001; Supplemental Table
2).
Among the 12,249 PLWH who were free of anemia at
baseline, 265 developed chronic anemia (lasting for at
least 6 months), during follow-up for an incidence of
0.46/100 person-years. For chronic anemia, associations
with patient characteristics were similar to those in the
primary analysis of anemia. (Table 3).
Average hemoglobin levels remained steady during
follow-up; the median level was 14.3 g/dL (IQR 13.1–
15.2) at baseline and 14.3 g/dL (IQR 13.1–15.3) at the
Table 2 Factors associated with developing anemia or severe
anemia in multivariable adjusted analyses among those free of
anemia (n = 12,249) or among those free of severe anemia
(n = 14,301) at baseline
Participant characteristics Anemia
n = 12,249
Hazard ratio
(95%CI)
Severe anemia
n = 14,301
Hazard ratio
(95% CI)
Age per 10 years 1.11 (1.04, 1.18) 1.05 (0.95, 1.16)
Female (ref male) 2.45 (2.12, 2.82) 2.09 (1.69, 2.58)
Race/ethnicity (ref white)
Black 1.19 (1.03, 1.39) 0.83 (0.65, 1.05)
Hispanic 0.90 (0.72, 1.13) 1.06 (0.76, 1.47)
Other/missing 0.99 (0.71, 1.39) 1.13 (0.69, 1.86)
Hepatitis C virus coinfection 1.79 (1.56, 2.05) 1.62 (1.31, 1.99)
CD4 cell count (cells/mm3) (ref ≥500)
350–499 1.38 (1.16, 1.65) 2.23 (1.68, 2.97)
200–349 1.67 (1.39, 2.02) 2.39 (1.78, 3.22)
100–199 2.83 (2.28, 3.62) 3.89 (2.77, 5.45)
< 100 8.40 (6.85, 10.51) 15.53 (11.56, 20.92)
Viral load ≥400 copies/ml 1.43 (1.23, 1.64) 1.86 (1.48, 2.34)
Kidney function (eGFR) (ref > 60)
30–60 2.35 (1.91, 2.89) 2.67 (1.97, 3.63)
< 30 17.84 (13.94, 24.02) 23.01 (17.85, 29.68)
ART use 0.92 (0.80, 1.05) 1.00 (0.81, 1.23)
BMI (ref 18.5- < 25)
< 18.5 0.89 (0.59, 1.32) 1.23 (0.77, 1.96)
25.0 to < 30.0 0.88 (0.77, 1.02) 0.73 (0.58, 0.91)
≥ 30.0 1.02 (0.87, 1.20) 0.92 (0.72, 1.17)
Smoking status (ref never)
Former 0.89 (0.75, 1.06) 0.82 (0.63, 1.07)
Current 1.08 (0.94, 1.25) 0.90 (0.72, 1.12)
Hazardous alcohol usea 0.93 (0.81, 1.06) 1.07 (0.87, 1.31)
Illicit drug useb 0.99 (0.86, 1.14) 0.99 (0.77, 1.21)
a Hazardous alcohol use defined a score of ≥4 for women or ≥ 5 for men on
the AUDIT-C scale
b Use of cocaine/crack, methamphetamines/crystal, and/or illicit opioids
Abbreviations: ART: antiretroviral therapy; BMI: body mass index; eGFR:
estimated glomerular filtration rate
Table 3 Factors associated with developing chronic anemia in
analyses among those without anemia at baseline; n = 12,249
Participant characteristics Hazard ratio 95% CI
Age per 10 years 1.18 1.04, 1.34
Female (ref male) 3.25 2.48, 4.27
Race/ethnicity (ref white)
Black 1.96 1.43, 2.68
Hispanic 1.29 0.82, 2.04
Other/missing 1.12 0.54, 2.33
Hepatitis C virus coinfection 1.76 1.32, 2.36
CD4 cell count (cells/mm3) (ref ≥500)
350–499 1.10 0.77, 1.56
200–349 1.93 1.40, 2.67
100–199 1.83 1.17, 2.88
< 100 4.11 2.67, 6.33
Viral load ≥400 copies/ml 1.86 1.48, 2.34
Kidney function (eGFR) (ref > 60)
30–60 1.31 0.72, 2.37
< 30 5.40 2.35, 12.42
ART use 0.99 0.73, 1.35
BMI (ref 18.5- < 25)
< 18.5 0.75 0.31, 1.85
25.0 to < 30.0 0.85 0.64, 1.14
≥ 30.0 0.82 0.59, 1.15
Self-reported smoking (ref never)
Former 0.82 0.57, 1.16
Current 0.93 0.70, 1.24
Hazardous alcohol usea 0.86 0.66, 1.12
Illicit drug useb 0.87 0.64, 1.18
a Hazardous alcohol use defined a score of ≥4 for women or ≥ 5 for men on
the AUDIT-C scale
b Use of cocaine/crack, methamphetamines/crystal, and/or illicit opioids
Abbreviations: ART antiretroviral therapy, BMI body mass index, eGFR
estimated glomerular filtration rate
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last available measurement per person. Characteristics
that were associated with having a lower hemoglobin
level measured during follow-up time included: older
age, female sex, non-white race/ethnicity, HCV coinfec-
tion, lower CD4 cell count, higher VL, lower eGFR, ART
use, illicit drug use and BMI < 18.5; conversely, BMI be-
tween 25 to < 30 or BMI ≥ 30 was associated with higher
hemoglobin overtime. Other factors associated with a
higher hemoglobin level included being a current
smoker and reporting hazardous alcohol use (Table 4).
Discussion
Anemia is an important clinical condition among
PLWH. In this study of 15,126 PLWH in care in the
current treatment era (2010 and after) in the US, we ob-
served that factors including older age, female sex, black
race, HCV coinfection, lower CD4 cell counts, VL ≥400
copies/ml and lower eGFR were associated with an in-
creased risk of anemia.
Lower CD4 cell count has been previously identified
as a risk factor for anemia. The present study confirmed
these findings, however we report much larger increased
risks of anemia (HR = 8.40, 95%CI: 6.85, 10.51) and se-
vere anemia (HR = 15.53, 95%CI:11.56–20.92) among
PLWH with CD4 cell counts < 100 cells/mm3 than have
been previously reported [20–24]. Risks this large in
magnitude suggest that additional screening and careful
monitoring would potentially be useful among partici-
pants with CD4 levels < 100 cells/mm3. In addition, we
found that those with CD4 levels < 100 who were female
or who also had HCV coinfection were at an especially
high risk of anemia.
Similar to the present study, previous work has found
that comorbidities such as HCV infection [25, 26] and
poor kidney function [27] are associated with anemia
risk. Furthermore, the current recommended treatment
for chronic HCV has known side effects of reduced
hemoglobin levels and reversible anemia [25, 26]. Add-
itionally, high BMI has been associated with iron [28]
and vitamin B12 deficiencies [29] and a lower chance of
recovery from anemia among PLWH [30]. However, we
did not find strong evidence in the present study that
BMI is associated with anemia risk.
Prior work has also shown that smoking leads to in-
creased hemoglobin levels and a reduction in the detec-
tion of anemia because smoking reduces the oxygen
carrying capacity of red blood cells, to which the body re-
sponds to by increasing hemoglobin levels as a means to
counteract this reduction in oxygen carrying capacity [31].
However, limited research exists into potential associa-
tions between the use of other substances including alco-
hol or illicit drugs and anemia. We found that being a
current smoker was associated with small increases in
hemoglobin over time, but did not detect any measurable
differences in anemia risk related to current smoking, al-
cohol or other substance use in the present study.
In the early treatment era, use of zidovudine
(AZT), was a known cause of bone marrow suppres-
sion [32]. In more recent years, AZT use has de-
creased substantially as other, better-tolerated ART
medications have become available. Though prior re-
search has found that being on ART is associated
with lower anemia incidence and severity for most
PLWH [23, 33–35] due to the ability of ART to con-
trol HIV disease progression, we did not find an as-
sociation between ART use and a reduction in
anemia or severe anemia incidence in the present
Table 4 Characteristics associated with hemoglobin level over
follow-up time in analyses (linear mixed-effect model); N = 15,126
Participant characteristics Coeffa 95% CI P-value
Age per 10 years − 0.01 − 0.01, − 0.01 < 0.001
Female (ref male) −1.68 − 1.74, − 1.62 < 0.001
Race/ethnicity (ref white)
Black −0.75 − 0.80, − 0.70 < 0.001
Hispanic − 0.15 − 0.21, − 0.08 < 0.001
Other/missing −0.13 − 0.23, − 0.03 0.011
Hepatitis C virus coinfection − 0.21 −0.25, − 0.16 < 0.001
CD4 cell count (cells/mm3) (ref ≥500)
350–499 −0.18 − 0.19, − 0.16 < 0.001
200–349 −0.39 − 0.41, − 0.37 < 0.001
100–199 −0.81 − 0.83, − 0.78 < 0.001
< 100 −1.49 − 1.52, − 1.46 < 0.001
Viral load ≥400 copies/ml −0.09 − 0.11, − 0.07 < 0.001
Kidney function (eGFR) (ref > 60)
30–60 − 0.15 −0.16, − 0.13 < 0.001
< 30 −1.11 − 1.15, − 1.07 < 0.001
ART use − 0.03 −0.04, − 0.01 < 0.001
BMI (ref 18.5- < 25)
< 18.5 −0.24 − 0.37, − 0.10 0.001
25.0 to < 30.0 0.24 0.19, 0.29 < 0.001
≥ 30.0 0.16 0.10, 0.22 < 0.001
Self-reported smoking (ref never)
Former 0.05 −0.01, 0.11 0.055
Current 0.15 0.10, 0.20 < 0.001
Self-reported hazardous alcohol useb 0.13 0.09, 0.18 < 0.001
Self-reported illicit drug usec −0.19 −0.24, − 0.14 < 0.001
aCoefficient is the mean difference per year in hemoglobin (g/dL) for each
variable after adjustment for all other covariates presented in the table
b Hazardous alcohol use defined a score of ≥4 for women or ≥ 5 for men on
the AUDIT-C scale
c Use of cocaine/crack, methamphetamines/crystal, and/or illicit opioids
Abbreviations: ART antiretroviral therapy, BMI body mass index, eGFR
estimated glomerular filtration rate
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study. This may be explained by possible pro-anemic
side effects of certain types of currently used ART
regimens [36].
Strengths of this study include the large and geograph-
ically diverse study population, longitudinal data struc-
ture, and availability of information on behaviors
including smoking, alcohol use, and illicit drug use.
However, there are important limitations of this study,
including our inability to classify anemia based on red
cell indices, lack of information on hemoglobinopathies,
nutritional deficiencies, chemotherapy or other medica-
tions with bone marrow toxicity, instances of severe
bleeding, blood donation or blood transfusion, all of
which could impact hemoglobin levels at a given time
point, and the possibility of residual confounding due to
the observational nature of the study. Additionally, we
relied on self-report of smoking and substance use,
which may be underreported. Finally, because this study
was conducted among PLWH in care in the United
States, our findings may not generalize to PLWH who
are not in care or reside outside of the United States.
Conclusions
In conclusion, we found that factors including older age,
female sex, black race, HCV coinfection, lower CD4 cell
counts, VL ≥400 copies/ml, and lower eGFR were associ-
ated with an increased risk of anemia. Because anemia is
a treatable condition associated with increased morbidity
and mortality among PLWH, clinicians should be aware
of these risk factors. Hemoglobin levels should be moni-
tored routinely, especially among PLWH who have one
or more of the risk factors for anemia so that treatment
can be initiated if deemed necessary.
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